Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

Recruiting now · Phase 1/Phase 2

Conditions studied: Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma

In brief

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given through intravenous (IV) infusions, which means it will be administered directly into a vein. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Key facts

Study ID

NCT07227012

Run by

Pfizer

People needed

138

Starts

2025-12-01

Expected to finish

2028-10-17

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older at screening.
• Locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by AASLD criteria (for patients with cirrhosis). Participants without cirrhosis require histological confirmation of diagnosis.
• Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies.
• At least 1 measurable (as defined by RECIST 1.1 per investigator) and untreated lesion.
• Adequate hepatic, liver, and renal function
• No prior systemic therapy for HCC.
• ECOG performance status 0 or 1
• Child-Pugh Class A
• Key Exclusion Criteria:
• Moderate or severe ascites.
• History of hepatic encephalopathy.
• Participants with known active CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression.
• Clinically significant risk of hemorrhage or fistula.
• Participants with any history of another malignancy within 3 years.
• History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• Participants with active autoimmune diseases requiring systemic treatment within the past 2 years.
• Clinically significant cardiovascular disease within 6 months prior to the first dose.
• Major surgery or severe trauma within 4 weeks prior to the first dose or planned major surgery during the study.
• History of severe bleeding tendency or coagulation dysfunction.
• History of severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding, including bleeding event due to esophageal and/or gastric varices, within 6 months prior to the first dose.
• Participants with acute, chronic or symptomatic infections.
• Participants with history of immunodeficiency.

Where it is running

• Taipei Veterans General Hospital — Taipei, Taiwan (enrolling)
• Los Angeles General Medical Center — Los Angeles, California, United States (enrolling)
• USC/Norris Comprehensive Cancer Center / Investigational Drug Services — Los Angeles, California, United States (enrolling)
• USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
• Keck Medical Center of USC Pasadena — Pasadena, California, United States (enrolling)
• Moffitt Cancer Center at Speros — Land O' Lakes, Florida, United States (enrolling)
• Moffitt Cancer Center at SouthShore — Ruskin, Florida, United States (enrolling)
• Moffitt Cancer Center - International Plaza — Tampa, Florida, United States (enrolling)
• Moffitt Cancer Center - McKinley Campus — Tampa, Florida, United States (enrolling)
• Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
• Moffitt McKinley Hospital — Tampa, Florida, United States (enrolling)
• Moffitt Cancer Center at Wesley Chapel — Wesley Chapel, Florida, United States (enrolling)
• Memorial Hospital — Shiloh, Illinois, United States (enrolling)
• Siteman Cancer Center - Shiloh — Shiloh, Illinois, United States (enrolling)
• Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota, United States (enrolling)
• Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota, United States (enrolling)
• Allina Health Cancer Institute - United Hospital — Saint Paul, Minnesota, United States (enrolling)
• Siteman Cancer Center - St. Peters — City of Saint Peters, Missouri, United States (enrolling)
• Siteman Cancer Center - West County — Creve Coeur, Missouri, United States (enrolling)
• Siteman Cancer Center - North County — Florissant, Missouri, United States (enrolling)
• Pan American Center for Oncology Trials, LLC - Dorado Office — Dorado, United States of America, Puerto Rico (enrolling)
• Pan American Center for Oncology Trials, LLC - Mayaguez Office — Mayagüez, United States of America, Puerto Rico (enrolling)
• Pan American Center for Oncology Trials, LLC - Ponce Office — Ponce, United States of America, Puerto Rico (enrolling)
• Pan American Center for Oncology Trials, LLC — San Juan, Puerto Rico (enrolling)
• Taichung Veterans General Hospital — Taichung, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.